Phase II study of oxaliplatin reintroduction treated with biweekly S-1 plus oxaliplatin (SOX) in patients with metastatic colorectal cancer.(ORION2)

ABSTRACT: Interventions: Oxaliplatin 85 mg/m2, day1 S-1 80-120 mg/day, day 1-7 or alternate-day every 2 weeks Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2628628 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR